Back to News

CAPD Statement on FDA Efforts to Increase Transparency, Competition in Generic Drugs and Biosimilars

Debra Barrett, Executive Director of the Coalition for Affordable Prescription Drugs (CAPD), today issued the following statement in response to new guidance from the Food and Drug Administration (FDA), intended to enhance generic drug competition in the prescription drug marketplace:

“We are pleased to see the FDA guidance today on the requirement that manufacturers disclose whether an approved generic has made it to market or not. This not only gives FDA greater visibility into whether an approved generic is or is not available to patients in market, but it also increases transparency for generic manufacturers. Our hope is that this new guidance will bolster timely competition from generics and biosimilars and ultimately, drive down high prices for patients.

“We are encouraged by Commissioner Gottlieb and the FDA’s continued efforts to increase transparency and competition.”

About CAPD

The Coalition for Affordable Prescription Drugs (CAPD) is a diverse group of employers, unions, public sector employees and retirees who partner with pharmacy benefit managers (PBMs) to provide more affordable prescription drug coverage for millions of Americans.